Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

749P - Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Date

21 Oct 2023

Session

Poster session 11

Topics

Clinical Research;  Immunotherapy

Tumour Site

Endometrial Cancer

Presenters

Giorgio Valabrega

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

G. Valabrega1, M.A. Powell2, S. Hietanen3, E.M. Miller4, Z. Novák5, R. Holloway6, D. Denschlag7, T. Myers8, A.M. Thijs9, K. Pennington10, L. Gilbert11, E. Fleming12, L. Copeland13, R. Gogoi14, I. Podzielinski15, N. Cloven16, O. Meyers17, J. Garside18, M.R. Mirza19, D. Black20

Author affiliations

  • 1 Department Of Oncology, University of Torino, AO Ordine Mauriziano, 10060 - Torino/IT
  • 2 Department Of Obstetrics And Gynecology, National Cancer Institute Sponsored NRG Oncology, Washington University School of Medicine, St. Louis/US
  • 3 Department Of Obstetrics And Gynecology, University of Turku and Turku University Hospital, 20521 - Turku/FI
  • 4 Division Of Gynecologic Oncology, West Penn Hospital, Pittsburgh/US
  • 5 Department Of Gynecology, Hungarian National Institute of Oncology, 1051 - Budapest/HU
  • 6 Department Of Gynecologic Oncology, AdventHealth Cancer Institute, Orlando/US
  • 7 Department Of Gynecology, AGO Study Group and Hochtaunus-Kliniken, Hospital Bad Homburg, Bad Homburg/DE
  • 8 Department Of Gynecologic Oncology, GOG-F and Baystate Medical Center, 01199 - Springfield/US
  • 9 Oncology Department, Catharina Een Santeon Ziekenhuis, 5602 ZA - Eindhoven/NL
  • 10 Division Of Gynecologic Oncology, Department Of Obstetrics And Gynecology, University of Washington, WA 98109 - Seattle/US
  • 11 Division Of Gynecologic Oncology,, McGill University Health Centre, H4A 3J1 - Montreal/CA
  • 12 Division Of Gynecologic Oncology, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon/US
  • 13 Department Of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, Hillard/US
  • 14 Department Of Obstetrics And Gynecology, C.S. Mott Center for Human Growth and Development, Wayne State University, and Karmanos Cancer Institute, 48202 - Detroit/US
  • 15 Department Of Gynecologic Oncology, Parkview Cancer Institute - Parkview Health, 46845 - Fort Wayne/US
  • 16 Department Of Gynecologic Oncology, Texas Oncology, U.S. Oncology Research Network, 76104 - Fort Worth/US
  • 17 Value, Evidence, And Outcomes, GSK, Collegeville/US
  • 18 Value Evidence And Outcomes, Oncology, GSK, Middlesex/GB
  • 19 Department Of Gynaecologic Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit, 2100 - Copenhagen/DK
  • 20 Department Of Obstetrics And Gynecology, LSU Health Shreveport and Willis-Knighton Physician Network, Shreveport/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 749P

Background

In the RUBY (NCT03981796) trial, dostarlimab (D)+carboplatin/paclitaxel (CP) demonstrated significant PFS improvement compared to placebo (PBO)+CP in pts with pA/rEC. PROs are reported here for the dMMR/MSI-H population.

Methods

Pts with pA/rEC were randomized 1:1 to D+CP or PBO+CP Q3W (6 cycles) followed by D or PBO monotherapy Q6W ≤3 years or disease progression. EORTC QLQ-C30 and EORTC QLQ-EN24 were secondary endpoints. PROs were administered at baseline (BL), day 1 of each cycle (C), end of treatment (EOT), and all follow-ups. Change (chg) from BL to EOT was calculated for assessed scales. Mixed models for repeated measures were used to generate least-squares means (LSM), adjusting for within-pt correlations across time points within a pt and controlling for BL values. Improvement is indicated by higher scores for QoL and functional scales and lower scores for symptom scales.

Results

Of 494 pts enrolled, 118 were dMMR/MSI-H. Mean BL scores and mean chg from BL to EOT for global QoL, functional scales, and select symptom are shown in the table. Mean chg from BL to EOT showed improvement in global QoL, emotional and social function, pain, and back/pelvis pain for D+CP. Only back/pelvis pain showed improvement for PBO+CP. Significant differences (LSM [standard error]) between arms were reported for chg from BL to EOT for QoL (14.7 [5.45]; P=0.008), role (12.7 [5.92]; P=0.032), emotional (14.3 [4.92]; P=0.004) and social function (13.5 [5.43]; P=0.014), and fatigue (-13.3 [5.84]; P=0.025).

Conclusions

Pts receiving D+CP demonstrated improvements in several QoL domains relative to BL at EOT, with significant improvements over PBO+CP, in global QoL, role, emotional, and social function, and fatigue. Dostarlimab+CP significantly improved PFS while maintaining QoL, further supporting its use as a standard of care in pts with dMMR/MSI-H pA/rEC. Table: 749P

D+CP PBO+CP
BL Mean (SD) BL to EOT Mean chg (SD) BL Mean (SD) BL to EOT Mean chg (SD)
EORTC QLQ-C30
Global QoL 66.7 (25.9) 3.0 (19.4) 67.3 (23.9) -11.1 (29.1)
Physical F 74.9 (21.8) -5.0 (17.1) 69.1 (23.3) -6.1 (26.9)
Role F 66.6 (32.2) 0.9 (29.7) 72.9 (32.2) -7.8 (36.6)
Emotional F 75.9 (18.1) 9.2 (17.5) 75.9 (20.1) -6.7 (30.4)
Cognitive F 86.3 (20.7) -1.5 (17.8) 88.0 (19.3) -9.3 (31.5)
Social F 74.5 (30.3) 6.1 (34.7) 80.2 (27.2) -12.0 (33.8)
Pain a 32.3 (27.3) -3.0 (29.7) 32.3 (32.1) 8.2 (32.8)
Fatigue a 33.9 (25.2) -5.1 (26.9) 35.1 (27.7) 7.2 (36.0)
EORTC QLQ-EN24
Back and pelvis pain a 35.3 (31.0) -10.8 (24.0) 36.5 (32.7) -3.1 (38.3)

aLower scores indicate reduced symptom severity F, function

Clinical trial identification

NCT01847274.

Editorial acknowledgement

Writing and editorial support, funded and coordinated by GSK, was provided by Shannon Morgan-Pelosi, PhD, and Mary C. Wiggin, of Ashfield MedComms, an Inizio company.

Legal entity responsible for the study

GSK.

Funding

GSK.

Disclosure

G. Valabrega: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, AstraZeneca, Clovis Oncology, GSK, PharmaMar, Roche, Tesaro. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Tesaro, Merck, Eisai, Clovis Oncology, AstraZeneca. S. Hietanen: Financial Interests, Personal, Other: GSK; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Orion Pharma; Financial Interests, Personal, Expert Testimony: AstraZeneca, GSK. E.M. Miller: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK, Tempus; Financial Interests, Personal, Other: OncLive, Opinions in Gyn Malignancies. Z. Novák: Financial Interests, Personal, Speaker, Consultant, Advisor: Sofmedica, AstraZeneca, MSD, Preglem; Financial Interests, Personal, Advisory Board: Richter Gedeon; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Stocks/Shares: Richter Gedeon. R. Holloway: Financial Interests, Personal, Other: GSK, AstraZeneca, Clovis, Eisai, Merck; Financial Interests, Personal, Stocks or ownership: Genelux. D. Denschlag: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, GSK/Tesaro, Roche, Eisai Germany, MSD Oncology, MSD, Intuitive Surgical, KLS Martin; Financial Interests, Personal, Other, travel expenses: AstraZeneca; Financial Interests, Personal, Other: Roche. T. Myers: Financial Interests, Personal, Other: Immunogen. A.M. Thijs: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, and Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck; Financial Interests, Personal, Other: Alkermes, AstraZeneca, Eisai, Eisai-Merck, and GSK. L. Gilbert: Financial Interests, Institutional, Funding: Alkermes, AstraZeneca, Clovis, Esperas, IMV, ImmunoGen Inc., Karyopharm, Merck Sharp & Dohme, Mersana, Novocure GmbH, OncoQuest Pharmaceuticals, Pfizer, Roche, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, AstraZeneca, Eisai, Eisai-Merck, GSK; Financial Interests, Personal, Other: Alkermes. L. Copeland: Financial Interests, Institutional, Funding: AbbVie, Advaxis, Agenus, Ajinomoto, Arcus Biosciences Inc., Array BioPharm, AstraZeneca, BeiGene USA Inc., BMS, Cerulean Pharma, Clovis Oncology, Deciphera Pharma, Eisai, EMD Serano, Ergomed Clinical Research, Exelixis, Genetech/Roache, Genmab, GSK, Hoffmann-LaRoche, Immunogen, Leap Therapeutics, Ludwig Institute of Pharmaceuticals, Merck, Mersana Therapeutics, Novocure, OncoQuest, PharmaMar USA, Pfizer, PRA International, Precision Therapeutics, Regeneron, Sanofi, Seattle Genetics, Serono, Stemcentrix, Sumitomo Dainippon Pharma Oncology, Sutro Biopharm, Tesaro (GSK), TRACON Pharm, Verastem; Financial Interests, Personal, Advisory Board: A28 Therapeutics, Celsion Corporation, Corcept Therapeutics, Elevar Therapeutics, GSK, Immunogen, Inx Med, Luzsana Biotechnology, Myriad Genetics, OncoNova, Rubius Therapeutics, Sorrento Therapeutics, Toray Industries, Inc., VBL Therapeutics; Financial Interests, Personal, Member: DMCC for Corcept Therapeutics. R. Gogoi: Financial Interests, Personal, Advisory Board: Pionyr Pharmaceuticals; Financial Interests, Personal, Other: Bausch + Lomb. N. Cloven: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, Toray Pharmaceuticals. O. Meyers, J. Garside: Financial Interests, Personal, Full or part-time Employment: GSK. M.R. Mirza: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK; Financial Interests, Personal, Member of Board of Directors: Karyopharm; Financial Interests, Personal, Stocks/Shares: Karyopharm; Financial Interests, Institutional, Research Grant: GSK, AstraZeneca, ultimovacs, Apexigen; Financial Interests, Institutional, Trial Chair: Deciphera; Non-Financial Interests, Advisory Role: Ultimovacs, Apexigen. D. Black: Financial Interests, Institutional, Funding: GSK; Financial Interests, Personal, Membership or affiliation: GOG Partners Investigational Council; Financial Interests, Personal, Ownership Interest: Trials365, LLC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.